Abstract
Amyloid-ß protein (Aß) is not only present in brain parenchyma in the form of
senile plaques (SPs), but also exists in the brain capillary vessels; the latter is defined as the
cerebral amyloid angiopathy (CAA), which is a recognized prominent pathological feature of
Alzheimer disease (AD). CAA occurs sporadically, being observed in approximately 85%–95%
of AD patients. The advanced CAA leads to spontaneous lobar hemorrhages and ischemic
lesions/infarcts. In contrast to SPs that are largely composed of Aß1-42, the CAA contains
predominately Aß1-40. The levels of SPs and CAA are inter-exchangeable by altering the ratio of
Aß1-42 and Aß1-40. Human apoEe4, a sporadic AD risk factor, also facilitates the formation of
CAA over SPs. CAA-mediated hemorrhage is closely associated with activated microglial cells
and astrocytes11. Recently, many Aß immunotherapies were shown to increase cerebral micro-
hemorrhages associated with amyloid-laden vessels, although not all immunotherapies are
alike. It appears there are distinct molecular mechanisms underlying SPs- and CAA-mediated
AD development. Currently, Pb remains to be a major public health concern. We showed Pb
exposure elevated and kept high ratios of brain Aß40/42 that favored CAA formation.
Additionally, Pb-induced amyloid deposition and overexpression of transforming growth factor-ß
(TGF-ß), a risk factor for CAA formation, were found in leptomeninges. We therefore propose to
test whether Pb in two different APP transgenic mouse lines is able to induce inflammation-
associated CAA that leads to cerebral microhemorrhages by using USPIO MRI/18F-AV45 PET
and immunohistochemistry (IHC), and the Pb-induced CAA results from TGF-ß1-induced
expressions of PAI and fibronectin to disrupt the perivascular drainage and/or enhance binding
of Aß to cerebrovasculature. Additionally, human anti-Aß antibodies and TM5275, a specific
inhibitor of PAI-1, will be used to further test our hypothesis. We believe that our hypothesis will
reveal, for the first time in literature, the CAA, independent of SPs, as the responsible
mechanism for Pb-mediated AD pathogenesis/development and this study will provide the
opportunity to develop the early diagnostic method and effective anti-Aß therapies for AD.